Phathom Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Phathom Pharmaceuticals (PHAT).

Price Target Range — 11 Quarters

Analyst Consensus — 8 Analysts

6Buy

2Hold

Consensus RatingBuy# Analysts8Avg. Consensus PT$18Upside to Avg. PT+145.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 9, 2026	Leerink Partners	Daniel Clark	Initiate	Market Perform	$10
Aug 17, 2026	Barclays	Glen Santangelo	PT Cut	Overweight	$18→$14
Jul 31, 2026	Guggenheim	Yatin Suneja	PT Cut	Buy	$25→$22
Jul 31, 2026	HC Wainwright & Co.	Matthew Caufield	Maintained	Buy	$26
Jul 30, 2026	Needham	Joseph Stringer	PT Cut	Buy	$28→$22
Jun 17, 2026	HC Wainwright & Co.	Matthew Caufield	Maintained	Buy	$26
Mar 27, 2026	Barclays	Glen Santangelo	Upgrade	Equal-Weight→Overweight	$16→$18
Feb 27, 2026	Guggenheim	Yatin Suneja	PT Raise	Buy	$20→$25
Dec 9, 2025	Barclays	Glen Santangelo	Initiate	Equal-Weight	$16
Oct 31, 2025	HC Wainwright & Co.	Matthew Caufield	PT Raise	Buy	$20→$26
Jun 9, 2025	Craig-Hallum	Chase Knickerbocker	PT Raise	Buy	$12→$17
Jun 9, 2025	HC Wainwright & Co.	Matthew Caufield	Maintained	Buy	$20
Jun 6, 2025	Needham	Joseph Stringer	Maintained	Buy	$28
May 2, 2025	Craig-Hallum	Chase Knickerbocker	PT Cut	Buy	$19→$12
May 2, 2025	Goldman Sachs	Paul Choi	PT Cut	Neutral	$10→$5
May 2, 2025	Guggenheim	Yatin Suneja	PT Cut	Buy	$18→$12
May 2, 2025	HC Wainwright & Co.	Matthew Caufield	PT Cut	Buy	$28→$20
Apr 21, 2025	Needham	Joseph Stringer	Maintained	Buy	$28
Apr 17, 2025	Goldman Sachs	Paul Choi	PT Cut	Neutral	$12→$10
Apr 9, 2025	Needham	Joseph Stringer	Maintained	Buy	$28

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Leerink Partners Initiates Coverage On Phathom Pharmaceuticals with Market Perform Rating, Announces Price Target of $10

Leerink Partners analyst Daniel Clark initiates coverage on Phathom Pharmaceuticals (NASDAQ:PHAT) with a Market Perform rating and announces Price Target of $10.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Phathom Pharmaceuticals, Lowers Price Target to $14

Barclays analyst Glen Santangelo maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Overweight and lowers the price target from $18 to $14.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Phathom Pharmaceuticals, Lowers Price Target to $22

Guggenheim analyst Yatin Suneja maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and lowers the price target from $25 to $22.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target

HC Wainwright & Co. analyst Matthew Caufield reiterates Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and maintains $26 price target.

Benzinga Newsdesk

PRO
Needham Maintains Buy on Phathom Pharmaceuticals, Lowers Price Target to $22

Needham analyst Joseph Stringer maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and lowers the price target from $28 to $22.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target

HC Wainwright & Co. analyst Matthew Caufield reiterates Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and maintains $26 price target.

Benzinga Newsdesk

Phathom Pharmaceuticals Inc

Phathom Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Leerink Partners Initiates Coverage On Phathom Pharmaceuticals with Market Perform Rating, Announces Price Target of $10

PRO
Barclays Maintains Overweight on Phathom Pharmaceuticals, Lowers Price Target to $14

PRO
Guggenheim Maintains Buy on Phathom Pharmaceuticals, Lowers Price Target to $22

PRO
HC Wainwright & Co. Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target

PRO
Needham Maintains Buy on Phathom Pharmaceuticals, Lowers Price Target to $22

PRO
HC Wainwright & Co. Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target

People Also Watch

People Also Watch

Phathom Pharmaceuticals Inc

Phathom Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROLeerink Partners Initiates Coverage On Phathom Pharmaceuticals with Market Perform Rating, Announces Price Target of $10

PROBarclays Maintains Overweight on Phathom Pharmaceuticals, Lowers Price Target to $14

PROGuggenheim Maintains Buy on Phathom Pharmaceuticals, Lowers Price Target to $22

PROHC Wainwright & Co. Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target

PRONeedham Maintains Buy on Phathom Pharmaceuticals, Lowers Price Target to $22

PROHC Wainwright & Co. Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target

People Also Watch

People Also Watch

PRO
Leerink Partners Initiates Coverage On Phathom Pharmaceuticals with Market Perform Rating, Announces Price Target of $10

PRO
Barclays Maintains Overweight on Phathom Pharmaceuticals, Lowers Price Target to $14

PRO
Guggenheim Maintains Buy on Phathom Pharmaceuticals, Lowers Price Target to $22

PRO
HC Wainwright & Co. Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target

PRO
Needham Maintains Buy on Phathom Pharmaceuticals, Lowers Price Target to $22

PRO
HC Wainwright & Co. Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target